ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "remission"

  • Abstract Number: 0844 • ACR Convergence 2021

    Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort

    Stephanie Keeling1, Britney Jones2, Jill Hall3, Joanne Homik4, Anthony Russell1, Luck Lukusa5, Sasha Bernatsky6 and Walter Maksymowych7, 1Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 2University of Alberta/University of Calgary, Edmonton, AB, Canada, 3Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 6McGill University, Montréal, QC, Canada, 7Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada

    Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…
  • Abstract Number: 0522 • ACR Convergence 2021

    Genetics of Rheumatoid Arthritis Remission; HLA-SE Associated with Remission in Anti-CCP Positive Patients

    Marc Maurits1, Samantha Jurado Zapata1, Yann Abraham2, Erik van den Akker1, Anne Barton3, Philip Brown4, Andrew P Cope5, Isidoro Gonzalez-Alvaro6, Carl Goodyear7, Annette H.M van der Helm-van Mil1, Xinli Hu8, Tom WJ Huizinga1, Martina Johannesson9, Lars Klareskog10, Dennis Lendrem11, Iain McInnes12, Fraser Morton7, Caron Paterson7, Duncan Porter13, Arthur Pratt11, Luis Rodriguez Rodriguez14, Daniela Sieghart15, Paul Studenic16, Suzanne Verstappen17, Leonid Padyukov9, Aaron Winkler18, John Isaacs19 and Rachel Knevel1, 1Leiden University Medical Center, Leiden, Netherlands, 2Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium, 3University of Manchester, Manchester, United Kingdom, 4Newcastle University, Newcastle, United Kingdom, 5King's College London, London, United Kingdom, 6Rheumatology Service. La Princesa University Hospital, Madrid, Spain, 7University of Glasgow, Glasgow, United Kingdom, 8Pfizer, Saint Peters, MO, 9Karolinska Institutet, Stockholm, Sweden, 10Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 11Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 12University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 13University of Glasgow, Bearsden, United Kingdom, 14Hospital Clinico San Carlos, Madrid, Spain, 15Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 16Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 17School of Social Sciences, The University of Manchester, Manchester, United Kingdom, 18Pfizer, Cambridge, MA, 19Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) patients capable of reaching clinical remission potentially have a specific genetic profile that allows them to regain immune tolerance. The identification…
  • Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium

    Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis

    Angela Chun1, Lutfiyya Muhammad 2 and Deirdre De Ranieri 3, 1Lurie Children's Hospital, Chicago, Iowa, 2Northwestern University Feinberg School of Medicine, Chicago, 3Lurie Children's Hospital, Chicago, Illinois

    Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
  • Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium

    Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile

    Sara Concha1, Pamela Morales 2, Eduardo Talesnik 1 and Arturo Borzutzky 1, 1Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, 2Department of Pediatric, Clinica Las Condes, Santiago, Chile

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
  • Abstract Number: L08 • 2019 ACR/ARP Annual Meeting

    Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial

    Siri Lillegraven1, Nina Sundlisater 2, Anna-Birgitte Aga 3, Joe Sexton 1, Inge Christoffer Olsen 4, Hallvard Fremstad 5, Cristina Spada 6, Tor Magne Madland 7, Christian Høili 8, Gunnstein Bakland 9, Åse Lexberg 10, Inger Johanne Widding Hansen 11, Inger Myrnes Hansen 12, Hilde Haukeland 13, Maud-Kristine Aga Ljoså 14, Ellen Moholt 15, Till Uhlig 16, Daniel Solomon 17, Désirée van der Heijde 18, Tore Kvien 16 and Espen A Haavardsholm 15, 1Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 4Oslo University Hospital, Oslo, Norway, 5Ålesund Hospital, Helse Møre og Romsdal, Ålesund, Norway, 6Lillehammer Hosptial for Rheumatic Diseases, Lillehammer, Norway, 7Haukeland University Hospital, Bergen, Norway, 8Hospital Østfold HF, Moss, Norway, 9University Hospital of North Norway, Tromsø, Norway, 10Drammen Hospital, Vestre Viken HF, Drammen, Norway, 11Sørlandet Hospital HF, Kristiansand, Norway, 12Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, 13Martina Hansens Hospital, Bærum, Norway, 14Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, 15Diakonhjemmet Hospital, Oslo, Norway, 16Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 17Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 18Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…
  • Abstract Number: L11 • 2019 ACR/ARP Annual Meeting

    Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Thomas W.J. Huizinga 4, Gustavo Citera 5, Clifton Bingham 6, Subhashis Banerjee 7, Benjamin Soule 8, Marleen Nys 9, Sean Connolly 10, Robert Wong 10, Kuan-Hsiang Gary Huang 7 and Roy Fleischmann 11, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 6Johns Hopkins University, Baltimore, 7Bristol-Myers Squibb, Princeton, NJ, 8Bristol-Myers Squibb, Princeton, New Jersey, 9Bristol-Myers Squibb, Braine L'Alleud, Belgium, 10Bristol-Myers Squibb, Princeton, 11Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
  • Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting

    Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis

    MASAOMI YAMASAKI1, 1Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
  • Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting

    Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Daniela DiGuiseppe 2, Anne Gitte Loft 3, Manuel Pombo-Suarez 4, Herman Mann 5, Ziga Rotar 6, Florenzo Iannone 7, Tore Kvien 8, Maria José Santos 9, Kari K. Eklund 10, Bjorn Gudbjornsson 11, Catalin Codreanu 12, Sema Yılmaz 13, Johan Askling 14, Carlos Sánchez-Piedra 15, Karel Pavelka 5, Matija Tomsic 16, Fabrizio Conti 17, Joe Sexton 18, Helena Santos 19, Nina Trokovic 20, Thorvardur J Love 21, Ruxandra IONESCU 22, Yavuz Pehlivan 23, Michael J. Nissen 24, Gary Macfarlane 25, Irene van der Horst-Bruinsma 26, Stylianos Georgiadis 27, Lykke Midtbøll Ørnbjerg 28, Cecilie Heegaard Brahe 28, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 4Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 5Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 6UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 7Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 11Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 12Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 13Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, 14Karolinska Institutet, Stockholm, Sweden, 15Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 16Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 17Sapienza University of Rome, Rome, Italy, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20Helsinki University Central Hospital, Helsinki, Finland, 21Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 22SPITALUL CLINIC SFANTA MARIA, Bucharest, 23Uludağ University, Bursa, Turkey, 24University Hospital Geneva, Geneva, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 28Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…
  • Abstract Number: 1684 • 2019 ACR/ARP Annual Meeting

    Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual

    Paolo Delvino 1, Federica Sardanelli 2, Pascal Cohen 3, Xavier Puéchal for the French Vasculitis Study Group 3, Luc Mouthon 3, Loic Guillevin 3 and Benjamin Terrier3, 1Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Vercelli, Italy, 2Department of Internal Medicine , Clinical Immunology Unit of Genoa and Policlinico San Martino, Genova, Italy, 3National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) require glucocorticoids (GCs) and immunosuppressants (IS) to induce and maintain remission. At the era of highly…
  • Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting

    6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Johan Askling 2, Catalin Codreanu 3, Herman Mann 4, Anne Gitte Loft 5, Manuel Pombo-Suarez 6, Ziga Rotar 7, Tore Kvien 8, Maria José Santos 9, Anna Mari Hokkanen 10, Florenzo Iannone 11, Bjorn Gudbjornsson 12, Fatos Onen 13, Lennart Jacobsson 14, Ruxandra IONESCU 15, Karel Pavelka 4, Carlos Sánchez-Piedra 16, Matija Tomsic 17, Joe Sexton 18, Helena Santos 19, Jenny Österlund 20, Alberto Cauli 21, Arni Jon Geirsson 22, Servet Akar 23, Adrian Ciurea 24, Gareth Jones 25, Irene van der Horst-Bruinsma 26, Cecilie Heegaard Brahe 27, Stylianos Georgiadis 28, Lykke Midtbøll Ørnbjerg 27, Mikkel Østergaard 29 and Merete Lund Hetland 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Karolinska Institutet, Stockholm, Sweden, 3Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 6Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 7UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Helsinki University Hospital, Helsinki, Finland, 11Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, 14Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, 15SPITALUL CLINIC SFANTA MARIA, Bucharest, 16Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 17Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, 21Universitá di Cagliari, Cagliari, Italy, 22Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 23Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 24University Hospital Zürich, Zürich, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 28DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 29Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 30DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
  • Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting

    Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Kuan-Hsiang Gary Huang 7, Sean Connolly 7, Yedid Elbez 8, Karissa Lozenski 9 and Roy Fleischmann 10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Princeton, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
  • Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting

    Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission

    Melanie Hagen1, Koray Tascilar 2, Michaela Reiser 3, Judith Haschka 4, Arnd Kleyer 5, Larissa Valor 6, Bernhard Manger 7, Georg Schett 8 and Jürgen Rech 9, 1Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 3Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 4Karl Landsteiner Institute for Gastroenterology and Rheumatology, St. Vincent Hospital Vienna, II Medical Department, Vienna, Austria, 5Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 6Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, 7Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, 8Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, 9Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
  • Abstract Number: 2511 • 2019 ACR/ARP Annual Meeting

    What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study

    Laura Coates1, Danielle Robinson 2, Ana-Maria Orbai 3, Uta Kiltz 4, Ying-Ying Leung 5, Penelope Palominos 6, Juan Cañete 7, Rossana Scrivo 8, Andra Balanescu 9, Emmanuelle Dernis 10, Sandra Talli 11, Adeline Ruyssen-Witrand 12, Lihi Eder 13, Maarten de Wit 14, Josef Smolen 15, Ennio Lubrano 16 and Laure Gossec 17, 1University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 5Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, 6Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, 7Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, 8Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, 9Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, 10Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 11Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, 12Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, 13Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, 14Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, 15Medical University of Vienna, Vienna, Austria, 1615. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy, 17Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

    Background/Purpose: In psoriatic arthritis (PsA), the objective of treatment is remission or low disease activity (LDA), but there is little research into patients’ perception of…
  • Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting

    Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells

    Jun Kikuchi1, Hironari Hanaoka 1, Shuntaro Saito 1, Tatsuhiro Oshige 1, Kazuoto Hiramoto 1, Yuko Kaneko 1, Noriyasu Seki 2, Hideto Tsujimoto 2 and Tsutomu Takeuchi 1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan

    Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…
  • Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting

    Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis

    Ekaterina Alexeeva1, Rina Denisova 2, Tatyana Dvoryakovskaya 2, Ksenia Isaeva 2, Ivan Kriulin 2, Alina Alshevskaya 3 and Andrey Moskalev 3, 1National Medical Research Center of Children`s Health, Moscow, Russia, 2NMRCCH, Moscow, Russia, 3Biostatistics and Clinical Trials Center, Novosibirsk, Russia

    Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences